

Roche, PathAI to develop AI digital pathology algorithms

Feb. 14, 2024—[Roche](#) announced it has entered into an agreement with [PathAI](#) to develop AI-enabled digital pathology algorithms for Roche Tissue Diagnostics' companion diagnostics business. Roche Tissue Diagnostics will work with PathAI as the sole external algorithm development company for AI-powered companion diagnostics and will continue to develop its own algorithms for companion diagnostics. PathAI will retain the ability to develop algorithms outside of companion diagnostics.

“This collaboration with Roche is a testament to our shared commitment to advancing the field of digital pathology and AI-enabled diagnostics for both drug development and clinical care,” Andy Beck, MD, PhD, CEO and cofounder of PathAI, said in a joint press release. “High medical value diagnostic products with seamless integration into the laboratory workflow will accelerate the transition to digital pathology as the standard to aid clinicians in diagnosis and biomarker characterization.”

Algorithms developed under the agreement will be deployed using Roche's digital pathology solution.